Innova Captab
Drug Manufacturers - Specialty & Generic · INNOVACAP
Small CapHealthcareHigh Growth
VL
Vinay Lohariwala
Managing Director · Pragmatic
Company DNA
Founder-Centric
About
Innova Captab is a Small Cap company in the Healthcare sector, listed on NSE as INNOVACAP. With a market cap of ₹4K Cr and revenue of ₹1K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Promoter-driven pharma company where decision-making authority is concentrated at the leadership level. Its strategic mandate: Needs to optimize manufacturing yield and regulatory compliance to capitalize on its CDMO expansion potential.
FAQ
What kind of company is Innova Captab?
Innova Captab is a Small Cap Healthcare company (INNOVACAP) in the High Growth phase with a market cap of ₹4K Cr. It is classified as Founder-Centric in culture.
What is Innova Captab's culture and work environment like?
Innova Captab has a Founder-Centric culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Promoter-driven pharma company where decision-making authority is concentrated at the leadership level.
Who leads Innova Captab?
Innova Captab is led by Vinay Lohariwala (Managing Director), a Pragmatic leader with 23 years of experience.
What are Innova Captab's financials?
Innova Captab reported revenue of ₹1K Cr in FY25 with a 5-year revenue CAGR of 15.6%. Operating margin: 13.4%. Market cap: ₹4K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
Promoter-driven pharma company where decision-making authority is concentrated at the leadership level.
Mandate
Needs to optimize manufacturing yield and regulatory compliance to capitalize on its CDMO expansion potential.
Needs to optimize manufacturing yield and regulatory compliance to capitalize on its CDMO expansion potential.
Financials
Revenue FY25₹1K Cr
PAT FY25₹128 Cr
Rev CAGR 5Y15.6%
OPM13.4%
NPM10.4%
ROE13.4%
ROCE13.5%
P/E30.9
Fwd P/E21.6
P/B4
D/E33
Mkt Cap₹4K Cr
Promoter72.2%
Institutional19.2%
Similar Culture
Could You Lead Innova Captab?
Take the Genome Benchmark →